Notably, antibody-mediated targeting of the Treg CCL2 high-affinity receptor, CCR4, reduced intertumoral Treg abundance and prolonged survival in a mouse glioma model [10, 11]. The gene discussed is CCL2; the disease is central nervous system cancer.